Abeona Therapeutics - ABEO Net Assets per Single Share

Graphic logo of abeonatherapeutics.com (ABEO)

Abeona Therapeutics (ABEO) is striving to commercialize a unique treatment method for rare skin pathologies, which guarantees high profits. Management is successfully developing the cellular platform, demonstrating transparency in its dealings with the FDA. This chart of current share prices on GURU.Markets shows they are at 2.24. Protection against generics is ensured by orphan drug status and strict quality standards, which create significant barriers to entry for competitors.

Abeona Therapeutics - ABEO Net Assets per Share (period 07/04/2022 - 10/28/2026)

Summary analytical data breakdowns for Abeona Therapeutics, Inc. (ABEO)

- price and consensus price forecast:
Stock Price Abeona|ABEO - Average Forecast Price
- market capitalization data:
Market Value Abeona Therapeutics Inc.|ABEO - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Abeona Therapeutics|ABEO - Book Valuation of Business|Market Value to Book Value Ratio abeonatherapeutics.com|ABEO - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Abeona Therapeutics|ABEO - Long-Term Liabilities to Capital|Short-Term Debt to Capital Abeona|ABEO - Company Total Debt|Debts to Book Capitalization Abeona Therapeutics Inc.|ABEO - Long-Term Debt Volume|Company Short-Term Debts Abeona Therapeutics
Analysis of all company metrics:abeonatherapeutics.com ABEO
Finished products of Abeona Therapeutics, Inc.

The published book value per share reflects the status of Abeona Therapeutics (ABEO) as a contender for a monopoly in the orphan disease gene therapy segment. This indicator is calculated as the ratio of net assets to the number of shares, measuring the actual asset backing of investments and protecting against overvalued assets, which confirms the company's financial stability as it prepares for the commercial launch of the high-cost drug Pz-cel.

Competitors of Abeona Therapeutics (ABEO)

VRTX (Vertex Pharmaceuticals Inc.) - Book Value per Share|ALNY: Net Asset Value per Share|Net Assets per Single Share INSM|UTHR (unither.com) - Net Asset Value per Share|BMRN: Net Assets per Single Share|Net Assets per Share BBIO|BGM - Net Assets per Single Share|Share Book Value Cogent Corp (COGT)|XERS: Book Value per Share|Net Asset Value per Share kerostx.com KROS|ARCT: Book Value per Share|ETON - Accounting Value per Share|Kamada Corp - Book Value per Share|Fulcrum Corp (FULC) - Net Assets per Share|MREO (Mereo BioPharma Group) - Book Value per Share|Book Value per Share PLX|Net Assets per Single Share Pliant Therapeutics (PLRX)|Net Assets per Single Share appliedtherapeutics.com (APLT)|Book Value per Share RNTX|GELS - Net Assets per Share|Accounting Value per Share Aytu Therapeutics|CMMB - Share Book Value|Book Value per Share SRXH|Polyrizon (PLRZ) - Net Asset Value per Share|Book Value per Share Aeterna Zentaris Inc (AEZS)|Equity per Share Cyclo Therapeutics, Inc (CYTH)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share